Skip to main content
. 2014 Apr 6;145(1):33–44. doi: 10.1007/s10549-014-2925-7

Table 3.

Association of HER2/HER3 dimerisation levels with biomarker expression in breast cancer

HER2/HER3 Status
Biomarker Unselected series HER2+ series
Low (%) High (%) p value (χ 2) Low (%) High (%) p value (χ 2)
Bcl-2
 Negative 207 (41.0) 53 (75.7) <0.001 (29.925) 32 (47.1) 80 (66.1) 0.010 (6.549)
 Positive 298 (59.0) 17 (24.3) 36 (52.9) 41 (33.9)
pAkt
 Negative 121 (25.4) 11 (15.5) 0.044 (3.295) 11 (29.7) 11 (19.6) 0.263 (1.255)
 Positive 356 (74.6) 60 (84.5) 26 (70.3) 45 (80.4)
PI3K
 Negative 122 (22.1) 7 (8.6) <0.001 (15.942) 4 (5.8) 5 (3.7) 0.105 (4.512)
 Moderate 143 (25.9) 13 (16.0) 12 (17.4) 11 (8.2)
 Strong 288 (52.0) 61 (75.3) 53 (76.8) 118 (88.1)
p21
 Negative 99 (79.2) 10 (90.9) 0.351 (0.871) 17 (45.9) (2.9) 12 (23.5) 0.027 (4.877)
 Positive 26 (20.8) 1 (9.1) 20 (54.1) 39 (76.5)
MUC-1
 Negative 69 (12.9) 2 (2.6) 0.020 (7.834) 4 (5.6) 4 (3.1) 0.581 (0.581)
 Moderate 243 (45.3) 43 (56.6) 39 (54.9) 66 (52.0)
 Strong 224 (41.8) 31 (40.8) 28 (39.4) 57 (44.9)
BRCA1
 Negative 317 (61.0) 59 (77.6) 0.005 (7.913) 48 (72.7) 85 (69.1) 0.603 (0.270)
 Positive 203 (39.0) 17 (22.4) 18 (27.3) 38 (30.9)
p53
 Negative 435 (71.7) 46 (48.9) <0.001 (19.524) 27 (36.0) 45 (31.5) 0.499 (0.457)
 Positive 172 (28.3) 48 (51.1) 48 (64.0) 98 (68.5)
PTEN
 Weak 79 (22.8) 3 (5.5) 0.006 (10.092) 0 (0.0) 5 (5.7) 0.265 (2.653)
 Moderate 130 (37.5) 21 (38.2) 21 (53.8) 40 (45.5)
 Strong 138 (39.8) 31 (56.4) 18 (46.2) 43 (48.9)
ER
 Negative 169 (28.3) 56 (60.2) <0.001 (37.424) 23 (31.1) 91 (62.8) <0.001 (19.699)
 Positive 429 (71.7) 37 (39.8) 51 (68.9) 54 (37.2)
 PgR
 Negative 264 (44.2) 65 (70.7) <0.001 (22.321) 36 (48.6) 100 (71.4) 0.001 (10.845)
 Positive 333 (55.8) 27 (29.3) 38 (51.4) 40 (28.6)

Bold values indicate significant values (p < 0.005)